2013 CME Meeting Series

Course Co-Chairs

Neil M. Bressler, MD
Neil M. Bressler, MD
The Johns Hopkins University*
School of Medicine
Baltimore, MD




Carl D. Regillo, MD
Carl D. Regillo, MD
Director, Retina Service
Wills Eye Institute
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA


Steering Committee

David S. Boyer, MD
Pravin U. Dugel, MD
SriniVas R. Sadda, MD

Overview

Anti-VEGF therapy revolutionized the management of neovascular age-related macular degeneration. As with any maturing therapeutic class, the clinical questions surrounding the use of anti-VEGF agents now focus on strategies to optimize therapy by identifying patients most likely to benefit and potential barriers to response that should be discussed with patients, determining the most effective dosing strategies with the various agents, and balancing the safety and efficacy of the available agents in the management of patients. Given the chronic nature of neovascular AMD, the long-term systemic effects of anti-VEGF injections are particularly relevant. In this program, leading vitreoretinal specialists will review the best data available to guide clinical decision-making, while also sharing their perspectives on managing challenging cases through interactive sessions.

*Participation by Neil M. Bressler, MD, in this activity does not constitute or imply endorsement by The Johns Hopkins University, The Johns Hopkins Hospital, or The Johns Hopkins Health System.